A novel post-exposure medical countermeasure L-97-1 improves survival and acute lung injury following intratracheal infection with Yersinia pestis

Innate Immunity

Volumn 18, Issue 3, 2012, Pages 373-389

  Wilson, Constance N ^a   Vance, Constance O ^a   Doyle, Timothy M ^b   Brink, David S ^b   Matuschak, George M ^b   Lechner, Andrew J ^b  

^a Endacea Inc   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

A1 adenosine receptors; lipopolysaccharide; medical countermeasure; plague; Yersinia pestis

Indexed keywords

ADENOSINE A1 RECEPTOR ANTAGONIST; CIPROFLOXACIN; L 97 1; UNCLASSIFIED DRUG; WATER;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; LEUKOCYTE; LUNG EDEMA; MALE; NONHUMAN; PLAGUE; RAT; SURVIVAL; YERSINIA PESTIS;

ACUTE LUNG INJURY; ANIMALS; CIPROFLOXACIN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUMANS; LIPOPOLYSACCHARIDES; LUNG; PLAGUE; PROTEIN BINDING; PURINES; RATS; RECEPTOR, ADENOSINE A1; VIRULENCE FACTORS; YERSINIA PESTIS;

ANIMALIA; NEGIBACTERIA; RATTUS; YERSINIA PESTIS;

EID: 84861827441     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425911411595     Document Type: Article

References (47)

1. Perry RD, Fetherston JD. Yersinia pestis-etiologic agent of plague. Clin Microbiol Rev. 1997 ; 10: 35-66
2. World Health Organization. Human plague in 2002 and 2003. Wkly Epidemiol Rec 2004; 79: 301-306.
3. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Plague as a biological weapon: Medical and public health management. JAMA. 2000 ; 283: 2281-2290
4. Inglesby TV, Grossman R, O'Toole T. A plague on your city: observations from TOPOFF. Clin Infect Dis. 2001 ; 32: 436-445
5. Gradon JD. Plague Pneumonia. Curr Infect Dis Rep. 2002 ; 4: 244-248
6. Anisimov AP, Amoako KK. Treatment of plague: Promising alternatives to antibiotics. J Med Microbiol. 2006 ; 55: 1461-1475
7. Bruneteau M, Minka S. Lipopolysaccharides of bacterial pathogens from the genus Yersinia: A mini-review. Biochimie. 2003 ; 85: 145-152
8. Dentovskaya SV, Bakhteeva IV, Titareva GM, Shaikhutdinova RZ, Kondakova AN, Bystrova OV, et al. Structural diversity and endotoxic activity of the lipopolysaccharide of Yersina pestis. Biochem. 2008 ; 73: 192-199
9. Neely CF, Jin J, Keith IM. A1-adenosine receptor antagonists block endotoxin-induced lung injury. Am J Physiol. 1997 ; 272: L353 - L361
10. Agar SL, Sha J, Foltz SM, Erova TE, Walberg KG, Parham TE, et al. Characterization of a mouse model of plague after aerosolization of Yersinia pestis CO92. Microbiol. 2008 ; 154: 1939-1948
11. Welkos S, Pitt MLM, Martinez M, Friedlander A, Vogel P, Tammariello R. Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague. Vaccine. 2000 ; 20: 2206-2214
12. Guarner J, Shieh W-J, Greer PW, Gabastou J-M, Chu M, Hayes E, et al. Immunohistochemical detection of Yersinia pestis in formalin-fixed, paraffin-embedded tissue. Am J Clin Pathol. 2002 ; 117: 205-209
13. Wilson CN, Batra VK. Lipopolysaccharide binds to and activates A(1) adenosine receptors on human pulmonary artery endothelial cells. J Endotoxin Res. 2002 ; 8: 263-271
14. Wilson CN, Vance CO, Goto M. A1 adenosine receptor antagonist, L-97-1, improves survival and acute lung injury following cecal ligation and perforation. J Leukocyte Biol. 2006 ;: 62-62
15. Doll JM, Zeitz PS, Ettestad P, Bucholtz L, Davis T, Gage K. Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona. Am J Trop Med Hyg. 1994 ; 51: 109-114
16. Straley SC, Bowmer WS. Virulence genes regulated at the transcriptional level by Ca2+ in Yersinia pestis include structural genes for outer membrane proteins. Infect Immun. 1986 ; 51: 445-454
17. Straley SC, Cibull ML. Differential clearance and host-pathogen interactions of YopE- and YopK-/YopL- Y. pestis in BALB/c mice. Infect Immun. 1989 ; 57: 1200-1210
18. Doyle TM, Matuschak GM, Lechner AJ. Septic shock and non-pulmonary organ dysfunction in pneumonic plague: The role of Y. pestis pCD1- vs. pgm- virulence factors. Crit Care Med. 2010 ; 38: 1574-1583
19. Matuschak GM, Doyle TM, Lechner AJ. Yersinia pestis KIM6+-induced lung pathobiology and systemic cytokine production. Crit Care Med. 2004 ; 32: A479 - A479
20. Lechner AJ, Doyle TM, Chen Z, Matuschak GM. Bacterial dissemination and systemic tissue inflammation following intratracheal infection of rats with Yersinia pestis. FASEB J. 2006 ; 20: 1381-1382
21. Lechner AJ, Ryerse JS, Matuschak GM. Acute lung injury during bacterial or fungal sepsis. Microsc Res Tech. 1993 ; 26: 444-456
22. Lechner AJ, Velasquez A, Knudsen KR, Johanns CA, Tracy TF, Matuschak GM. Cholestatic liver injury increases circulating TNF-α and IL-6 and mortality after E. coli endotoxemia. Am J Resp Crit Care Med. 1998 ; 157: 1550-1558
23. Prentice MB, Rahalison L. Plague. Lancet. 2007 ; 369: 1196-1207
24. Hepburn MJ, Purcell BK, Paragas J. Pathogenesis and sepsis caused by organisms potentially utilized as biologic weapons: Opportunities for targeted intervention. Curr Drug Targets. 2007 ; 8: 519-532
25. Lathem WW, Crosby SD, Miller VL, Goldman WE. Progression of primary pneumonic plague: A mouse model of infection, pathology, and bacterial transcriptional activity. Proc Nat Acad Sci. 2005 ; 102: 17786-17791
26. Van Amersfoort ES, Van Berkel TJC, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev. 2003 ; 16: 379-414
27. Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: Potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Micro Rev. 2002 ; 15: 95-110
28. Cornelius CA, Quenee LE, Overheim KA, Koster F, Brasel TL, Elli D, et al. Immunization with recombinant V10 protects Cynomolgus Macaques from lethal pneumonic plague. Infec Immun. 2008 ; 76: 5588-5597
29. Anderson DM, Ciletti NA, Lee-Lewis H, Elli D, Segal J, DeBord KL, et al. Pneumonic plague pathogenesis and immunity in Brown Norway rats. Am J Pathol. 2009 ; 174: 910-921
30. Lechner AJ, Doyle TM, Ryerse JS, Matuschak GM. Alveolar macrophages fail to kill avirulent Yersinia pestis despite rapid phagocytosis and induced production of TNF-α and IL-1β. Am J Respir Crit Care Med. 2006 ; 169: A232 - A232
31. Lawson JN, Lyons CR, Johnston SA. Expression profiling of Yersinia pestis during mouse pulmonary infection. DNA Cell Biol. 2006 ; 25: 608-616
32. Benner GE, Andrews GP, Byrne R, Strachan SD, Sample AK, Heath DG, et al. Immune response to Yersinia outer proteins and other Y. pestis antigens after experimental plague infection in mice. Infec Immun. 1999 ; 67: 1922-1928
33. Blackburn MR, Vance CO, Morschl E, Wilson CN Adenosine receptors in health and disease. Handbook of experimental pharmacology. Wilson CN Mustafa SJ, ed. Heidelberg: Springer-Verlag ; 2009: 215-269.
34. Funakoshi H, Zacharia LC, Zhonghua T, Zhang J, Lee LL, Good JC, et al. A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation. 2007 ; 115: 2307-2315
35. Mustafa SJ, Morrison RR, Teng B, Pelleg A Adenosine receptors in health and disease. Handbook of experimental pharmacology. Wilson CN Mustafa SJ, ed. Heidelberg: Springer-Verlag ; 2009: 161-188.
36. Neely CF, Haile DM, Cahill BE, Kadowitz PJ. Adenosine and adenosine 5'-triphosphate produce vasoconstriction in the feline pulmonary vascular bed by different mechanisms. J Pharmacol Exp Ther. 1991 ; 258: 753-761
37. Vallon V, Osswald H Adenosine receptors in health and disease. Handbook of experimental pharmacology. Wilson CN Mustafa SJ, ed. Heidelberg: Springer-Verlag ; 2009: 443-470.
38. Wilson CN, Nadeem A, Spina D, Brown R, Page CP, Mustafa SJ Adenosine receptors in health and disease. Handbook of experimental pharmacology. Wilson CN Mustafa SJ, ed. Heidelberg: Springer-Verlag ; 2009: 329-362.
39. Martin C, Leone M, Viviand X, Ayem M-L, Guieu R. High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. Crit Care Med. 2000 ; 28: 3198-3202
40. Jhaveri KA, Reichensperger J, Toth LA, Sekino Y, Ramkumar V. Reduced basal and lipopolysaccharide-stimulated adenosine A1 receptor expression in the brain of nuclear factor-κB p50-/-mice. Neurosci. 2007 ; 146: 415-426
41. Satoh A, Shimosegawa T, Satoh K, Ito H, Kohno Y, Masamune A, et al. Activation of adenosine A1-receptor pathway induces edema formation in the pancreas of rats. Gastroenterol. 2000 ; 119: 829-836
42. Neely CF, Keith I. A1 adenosine receptor antagonists block ischemia-reperfusion injury of the lung. Am J Physiol. 1995 ;: 268: L1036 - L1046
43. Factor P, Mutlu GM, Chen L, Mohameed J, Akhmedov AT, Meng FJ, et al. Adenosine regulation of alveolar fluid clearance. Proc Natl Acad Sci. 2007 ; 104: 4083-4088
44. Obiefuna PC, Batra VK, Nadeem A, Borron P, Wilson CN, Mustafa SJ. A Novel A1 adenosine receptor antagonist, L-97-1, [3-[2-(4-Aminophenyl)-ethyl]-8- benzyl-7-{2-[ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3, 7-dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma. J Pharmacol Exp Ther. 2005 ; 315: 329-336
45. Nadeem A, Obiefuna PC, Wilson CN, Mustafa SJ. A1 adenosine receptor antagonist versus montelukast on airway reactivity and inflammation. Eur J Pharmacol. 2006 ; 551: 116-124
46. Dhalla AK, Shryock JC, Shreeniwas R, Belardinelli L. Pharmacology and therapeutic application of A1 adenosine receptor ligands. Curr Top Med Chem. 2003 ; 3: 369-385
47. Lawrenz MB. Model systems to study plague pathogenesis and develop new therapeutics. Front Microbiol. 2010 ; 1: 1-9